Redeye provides a research update in regards to the Q3 report published by Alzinova earlier today. Overall, the report was in line with our expectations. However, the main focus right now is the upcoming readout form the crucial phase Ib study with ALZ-101. For now, as we await the study results, we reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Alzinova Q3 - All eyes on the readout

© Modular Finance, source Nordic Press Releases